Research Article

FGFRL1 Promotes Ovarian Cancer Progression by Crosstalk with Hedgehog Signaling

Haiyan Tai ¹, Zhiyong Wu,¹ Su'an Sun,² Zhigang Zhang ³, and Congjian Xu ^{1,4,5}

¹Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China

²Department of Pathology, The First Hospital of Huai'an City, Nanjing Medical University, Huai'an, 223001 Jiangsu, China

³State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University, Shanghai 200240, China

⁴Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai 200032, China

⁵Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China

Correspondence should be addressed to Zhigang Zhang; zzhang@shsci.org and Congjian Xu; xucongjian@fudan.edu.cn

Received 28 November 2017; Accepted 17 December 2017; Published 20 February 2018

Academic Editor: Jian Song

Copyright © 2018 Haiyan Tai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fibroblast growth factor receptor-like-1 (FGFRL1) has been identified as the fifth fibroblast growth factor receptor. So far, little is known about its biological functions, particularly in cancer development. Here, for the first time, we demonstrated the roles of FGFRL1 in ovarian carcinoma (OC). An array and existing databases were used to investigate the expression profile of FGFRL1 and the relationship between FGFRL1 expression and clinicopathological parameters. FGFRL1 was significantly upregulated in OC patients, and high FGFRL1 expression was correlated with poor prognosis. *In vitro* cell proliferation, apoptosis and migration assays, and *in vivo* subcutaneous xenograft tumor models were used to determine the role of FGFRL1. Loss of function of FGFRL1 significantly influenced cell proliferation, apoptosis, and migration of OC cells *in vitro* and tumor growth *in vivo*. Chromatin immunoprecipitation PCR analysis and microarray hybridization were performed to uncover the mechanism. FGFRL1 expression could be induced by hypoxia through hypoxia-inducible factor 1 α , which directly binds to the promoter elements of FGFRL1. FGFRL1 promoted tumor progression by crosstalk with Hedgehog (Hh) signaling. Taken together, FGFRL1 is a potential predictor and plays an important role in tumor growth and Hh signaling which could serve as potential therapeutic targets for the treatment of OC.

1. Introduction

Ovarian carcinoma (OC) has the highest mortality rate among the malignancies of the female reproductive tract. In the United States, more than 22,000 women were diagnosed with OC and more than 14,000 women died in 2016 [1]. The poor survival rate is due primarily to the advanced stage of disease and widespread metastases at the time of diagnosis. Therefore, an insight into the understanding of the molecular mechanisms underlying the progression of OC and identifying new targets and strategies is pressing.

Fibroblast growth factor-like-1 (FGFRL1) is a member of the fibroblast growth factor receptor (FGFR) family [2–6]. Fibroblast growth factors (FGF) and their receptors are

known for regulating numerous cellular processes. Activated FGFRs have become a promising potential target in many cancers, including ovarian carcinoma. FGFRL1 encoding the protein composed of a cytoplasmic His-rich motif without the intracellular tyrosine kinase domain. Owing to the fact, it was thought to be a decoy receptor and exert no or negative effect on cell proliferation in some studies [7, 8]. However, FGFRL1 is involved in multiple cellular functions. FGFRL1 was reported to take part in the progression of endometriosis [9] and induce cell-cell fusion in CHO cells [10]. Targeted deletion of FGFRL1 leads to severe kidney dysgenesis [11]. FGFRL1 was identified to enhance ERK1/2 signaling through association of SHP with the receptor's intracellular SH2-binding motif in beta-cells in the pancreas

[12]. In high-grade serous ovarian tumor, FGFR1 mRNA isoform was identified with tumor-specific expression [13]. FGFR1 could accelerate tumor growth in different neoplastic diseases [14–16]. However, little is known about cellular functions of FGFR1 in ovarian carcinoma.

Herein, we analyzed the expression pattern and clinical significance of FGFR1 in ovarian cancer and tried to detect important pathways as well as key genes in order to understand the mechanism of FGFR1 contributing to the development of ovarian cancer.

2. Material and Methods

2.1. Case Cohort. Human ovarian cancer tissue microarrays containing 90 cases of ovarian carcinoma and 10 cases of normal ovarian tissues were obtained from Obstetrics and Gynecology Hospital, Fudan University. The study was approved by the Research Ethics Committee of Obstetrics and Gynecology Hospital, Fudan University.

2.2. Cell Culture. Human ovarian cancer cell lines ES2, SKOV3, OVCAR8, Hey, and human immortalized ovarian epithelial cell line Moody were preserved at Shanghai Cancer Institute. All cells were cultured in indicated medium and supplemented with 10% fetal bovine serum (Invitrogen), 100 µg/ml streptomycin, and 100 units/ml penicillin at 37°C with 5% CO₂. Aiming to hypoxia treatment, OC cells were cultured in the incubator with 1% O₂ gas mixture for the desired period of time. Prior to CHIP assay, Cobalt chloride (CoCl₂) was used at the final concentration of 100 µM in the OC cell culture media and incubated for 6 hours to induce hypoxia [17].

2.3. Immunohistochemistry. The tissue microarray (TMA) slide was prepared for immunohistochemistry (IHC) staining, and the primary antibody FGFR1 (Rabbit polyclonal antibody, Novus) was used. The FGFR1 staining intensity was scored as follows: negative, 0; weak, 1; moderate, 2; and strong, 3. Scoring of positive staining cells was conducted from 0–4: 0–5%, 0; 6–35%, 1; 36–70%, 2; and more than 70%, 3. The final score was designated using FGFR1 staining intensity score × FGFR1-positive cell score. The final score was determined as follows: a score of 0 or 1 was considered low expression, and a score of 2 or 3 was considered high expression. The results were evaluated by two experienced pathologists in a blinded manner.

2.4. Real-Time PCR. The total RNA was extracted from OC cells using RNAiso Plus (Takara, Tokyo, Japan). The reverse transcription was performed using a Prime-Script RT-PCR Kit (Takara, Tokyo, Japan). The qPCR was performed using ABI 7500 System (Applied Biosystems Inc. USA) with SYBR Green Master Mix (Takara, Japan). The data were analyzed to quantify the relative mRNA expression levels of genes. The primers used in this study are shown in Supplementary Table S2.

2.5. Western Blotting. OC cells were lysed in IP lysis buffer (Beyotime, Jiangsu, China) containing proteinase and phosphatase inhibitors (Selleck, TX, USA). Proteins were

separated through SDS-PAGE and incubated overnight at 4°C using primary antibodies as follows: anti-FGFR1 (Abcam, UK, ab112917, 1:100) and HIF1α (Abcam, UK, Ab16066, 1:1000). The bands were detected using ECL Western Blotting Detection Reagents (Millipore).

2.6. Short Interfering RNA-Based Gene Knockdown. OC Cells were transiently transfected using the Lipofectamine RNAiMAX reagent (Invitrogen), Opti-MEM reduced-serum medium (Invitrogen), and small interfering RNA (siRNA) oligonucleotides (Supplementary Table S1) for FGFR1 silencing. After 48 hours, siRNA-treated cells were used in a subsequent experiment.

2.7. Cell Viability Assay. OC cells were transfected with FGFR1 siRNA. After 48 hours, cell viability was measured using Cell Counting Kit-8 (CCK-8, Dojindo, Japan). The absorbance was detected at 450 nm using a microplate reader. The experiment was performed in triplicate and repeated triple.

2.8. Migration Assay. About 2×10^4 cells in 200 µL medium were seeded into the upper chambers (Corning, NY, USA) with an 8 µm pore in 24-well plates. Medium containing 10% FBS was added to the lower chambers. After 16 hours, the cells which remained on the upper surface of the chambers were removed. The migrated cells were fixed and stained with crystal violet. The cells were counted in five random microscopic fields per well.

2.9. Wound Healing Assay. OC cells were seeded, and the wound was created by scraping with a pipette tip while cells were 90% confluent. After the debris was washed with PBS, photographs were taken to assess the ability of the cells to migrate into the wound area at 0 h and 24 h. Experiments were carried out in triplicate.

2.10. Apoptosis Assay. OC cells were cultured under serum deprivation overnight and detached with 0.25% trypsin without EDTA. Then cells were washed with $1 \times$ PBS, stained with 50 µg/ml propidium iodide and Annexin V-FITC (BD Pharmingen, USA) following the manufacturer's protocols. The percentage of Annexin V (+) and PI (–) cells was analyzed by flow cytometry.

2.11. Animal Experiments. Short hairpin RNA- (shRNA-) containing plasmids were packaged into lentivirus, and virus titers were determined. The sequence targeting FGFR1 is as follows: sh: 5'-GTCGTGCTGGATGACATTAGC-3'. For *in vivo* tumor formation, 2×10^6 sh-OVCAR8 cells were subcutaneously injected into one flank of each mouse. After 6 weeks, the mice were sacrificed, and the parameters were measured. Mice were manipulated and housed according to protocols approved by the East China Normal University Animal Care Commission.

2.12. Chromatin Immunoprecipitation (CHIP) Assay. CoCl₂ was used to induce hypoxia in the hypoxia group. Cells were cross-linked with 1% formaldehyde, terminated by adding glycine (1.25 M), lysed, and fragmented. The extracts were

FIGURE 1: FGFR1 expression is increased in OC. (a) The mRNA level of FGFR1 is unregulated in SBOT, LGSOC, and HGSOC compared with OSE in the GSE27651 dataset. Comparison of mRNA expression levels of FGFR1 in OSE and SOC tissues in the GSE18520 (b) and GSE12470 datasets (c). (d) The representative IHC staining of FGFR1 in OC and noncancerous samples in the TMA. Scale bar, 50 μ m. (e) Score of the IHC staining in the TMA of OC. (f) Correlation between FGFR1 expression and the patient overall survival was conducted in TCGA. (g) Comparisons of overall survival between the lower FGFR1 expression group and the higher FGFR1 expression group in patients with advanced grade (II-III). SBOT: serous borderline ovarian tumors; LGSOC: low-grade serous ovarian carcinomas; HGSOC: high-grade serous ovarian carcinomas; OSE: ovarian surface epithelia; SOC: serous ovarian carcinomas; OCCC: ovarian clear cell carcinoma; OEC: ovarian endometrioid adenocarcinoma; MOC: mucinous ovarian carcinoma; LN: lymphatic node. ** $p < 0.01$; *** $p < 0.001$.

incubated with the anti-HIF1 α antibody or control IgG with rotation overnight at 4°C. After IP, the protein DNA cross-links were reversed. PCR was performed with the input

DNA and the immunoprecipitates, and the products were separated by agarose gel electrophoresis. The primers used here are listed in Supplementary Table S2.

FIGURE 2: Continued.

FIGURE 2: FGFR1 could be induced by hypoxia via HIF1 α in OC. (a) FGFR1 DNA copy number amplification of OC in TCGA. (b) The mRNA expression level of FGFR1 was significantly induced after hypoxia treatment in SKOV3 cells in the GSE53012 dataset. (c, d) The protein levels of FGFR1 and HIF1 α stimulated by hypoxia at indicated time intervals in OC cells. (e, f) The protein levels of FGFR1 and HIF1 α under HIF1 α siRNA interference and hypoxia condition for 6 hours in OC cells. (g) 10 pairs of primers were constructed according to the promoter of FGFR1. (h) A ChIP assay was performed to confirm the potential HIF1 α binding site in the FGFR1 promoter region. (i) Two putative HIF1 α -binding sites in the FGFR1 promoter located at -2649 to -2632 and -27 to -11 (mutation site: red). (j, k) A luciferase reporter assay was performed using OC cells after transfecting the wild-type plasmids and mutated plasmids. The data shown are the mean $\pm$ SD. * $p < 0.05$; ** $p < 0.01$.

2.13. Dual-Luciferase Reporter Assay. FGFR1 promoter-luciferase reporter plasmids were constructed in the pGL4 plasmid. A dual luciferase reporter assay (Promega, WI, USA) was performed following the manufacturer's instructions.

2.14. Microarray Hybridization. Si-control/ES2, Si-FGFR1/ES2 cells, Si-control/OVCAR8, and Si-FGFR1/OVCAR8 cells were homogenized in RNAiso Plus (Takara, Tokyo, Japan). The Affymetrix human genome U133 gene chip sets were performed by Shanghai Biotechnology Corporation. Transcript profiling was submitted to the National Center for Biotechnology Information's GEO database, and the repository URL and the data accession numbers are GSE 106549.

2.15. Statistical Analysis. The SPSS 19.0 software (IBM Corporation) was used for statistical analyses. The comparisons were taken using two-tailed paired Student's t -tests. The correlation was performed by a chi-square or Fisher's exact tests. Graphic representations were tested with GraphPad Prism software (San Diego, CA). For survival analysis, the Kaplan-Meier method was carried out and differences were analyzed by the log-rank test. Values of $p < 0.05$ were considered to be statistically significant.

3. Results

3.1. The Expression of FGFR1 Is Upregulated in OC. By browsing databases, we found that FGFR1 was upregulated in various tumors. We analyzed three independent microarray datasets from GEO datasets for FGFR1 mRNA expression level. The results showed that FGFR1 expression was significantly upregulated in serous borderline ovarian tumors (SBOT), low-grade serous ovarian carcinomas (LGSOC), and high-grade serous ovarian carcinomas

(HGSOC) in comparison with ovarian surface epithelia (OSE) using GSE27651 ($n = 49$, $p = 0.0007$, $p < 0.0001$, and $p = 0.0013$; Figure 1(a)) [18]. FGFR1 expression was also significantly higher in SOC tissues than OSE or normal tissues using GSE18520 ($n = 63$, $p < 0.0001$; Figure 1(b)) [19] and GSE12470 ($n = 45$, $p < 0.0001$; Figure 1(c)) [20]. Subsequently, to further address the protein change of FGFR1 in OC, we performed IHC in a TMA of 90 OC samples and 10 noncancerous samples. The protein level of FGFR1 was remarkably higher in OC tissues than that in normal tissue by IHC (Figures 1(d) and 1(e)).

3.2. Relationship between FGFR1 Expression and Clinical Parameters of OC. To evaluate the clinical significance of FGFR1 expression in OC, we assessed the relationship between FGFR1 protein expression and clinical parameters (Supplementary Table S3). The results showed that FGFR1 expression was significantly associated with histological grading.

3.3. High FGFR1 Expression Predicts Poor Prognosis in OC. The correlation between FGFR1 expression and clinical follow-up information was analyzed in order to evaluate the prognostic significance of FGFR1 in OC patients. We evaluated the prognostic value of FGFR1 at mRNA level using a Kaplan-Meier plotter tool with a total of 1648 cases enrolled from TCGA (the Cancer Genome Atlas) and multiple GEO datasets. As shown in Figure 1(f), patients with higher FGFR1 level had significantly shorter survival time than those with a lower FGFR1 level. Furthermore, the relationship between FGFR1 expression and the overall survival in OC patients with advanced grade (II-III) was evaluated. The overall survival was shorter in advanced patients with high FGFR1 expression (Figure 1(g)).

FIGURE 3: Continued.

FIGURE 3: Silencing of FGFR1 suppresses OC cell proliferation and promotes cell apoptosis. (a) The mRNA and protein expression levels of FGFR1 were assessed in OC cell lines as well as a nonmalignant ovarian cell line Moody. (b) The qRT-PCR analysis of the FGFR1 expression after FGFR1 siRNA interference. (c) Successful FGFR1 silencing was confirmed by Western blotting. (d) The effect of FGFR1 on cell proliferation was determined by CCK8 assay. Knockdown of FGFR1 promoted apoptosis as revealed by caspase-3/7 activity (e) and flow cytometry (f). * $p < 0.05$; ** $p < 0.01$.

3.4. FGFR1 Gene Is Infrequently Amplified and Could Be Induced by Hypoxia via Hypoxia-Inducible Factor 1 α (HIF1 α) in OC. In order to identify whether gene amplification contributes to higher FGFR1 expression in OC, our analysis of cancer genomics in TCGA revealed that gene amplification was infrequent in FGFR1 gene and only 21 of 301 samples (6.75%; Figure 2(a)). The evidence is insufficient to explain the upregulation of FGFR1 expression in OC.

Thus, we need more evidence to explain the upregulation of FGFR1 expression. Hypoxia microenvironments are often found in many solid tumors including prostate cancer, brain tumor, and ovarian carcinomas [21–23]. Hypoxia treatments (2% O₂) were performed in OC cells. The existing dataset showed that FGFR1 expression was significantly induced after hypoxia treatment in SKOV3 cells in the GSE53012 dataset (Figure 2(b)). Our results revealed that the expression of FGFR1 was induced by hypoxia treatment in OC cells at indicated time intervals (Figures 2(c) and 2(d)).

We tried to identify transcription factor responsible for hypoxia-induced upregulation of FGFR1 expression. It has been reported that hypoxia-inducible factor 1 (HIF1) is a key molecule to help the hypoxia cells to compensate the hypoxia at the molecular level. Under hypoxic conditions, HIF-1 α subunit can be stabilized and accumulated. Our results also suggest that hypoxia can induce the expression of HIF1 α in OC cells.

To identify the role of HIF1 α , we first examined the FGFR1 expression level after HIF1 α silencing with siRNAs under hypoxia condition for 6 hours. HIF1 α knockdown reduced FGFR1 expression in OC cells (Figures 2(e) and 2(f)). These findings suggest that FGFR1 is the downstream target of HIF1 α in OC cells. We hypothesized that HIF1 α

directly regulated FGFR1 by transcription of the FGFR1 promoter and conducted 10 pairs of primers according to the promoter of FGFR1 (Figure 2(g)). We mimicked chemical hypoxia condition using CoCl₂ in OC cell for 6 hours. CHIP PCR was performed in OC cell and indicated that HIF1 α was directly bound to the second and tenth region in the FGFR1 promoter under the hypoxia condition (Figure 2(h)). Two putative HIF1 α -binding sites in the FGFR1 promoter located at –2649 to –2632 and –27 to –11 were identified (Figure 2(i)). We constructed the wild-type and mutant FGFR1 promoter luciferase reporters and used them in reporter assays. Reporter assays further confirmed that the transcriptional activity of FGFR1 was significantly induced by HIF1 α under hypoxia condition and was decreased by transduction of a mutant FGFR1 promoter luciferase reporter (Figures 2(j) and 2(k)). Collectively, our findings supported that HIF1 α could transcriptionally activate FGFR1 by binding to two predicted sites in the FGFR1 promoter.

3.5. FGFR1 Affects OC Cell Proliferation, Apoptosis, and Cell Migration In Vitro. Based on FGFR1 high expression with poor clinical prognosis, we further investigated the biological cellular functions of FGFR1 in OC cells. Consistent with the findings in OC tissues, FGFR1 expression was higher in OC cells than in a nonmalignant immortalized ovarian cell line Moody at protein level (Figure 3(a)). The siRNA-mediated loss of function for FGFR1 resulted in >75% reduction in FGFR1 expression in OC cells by RT-PCR and Western blot (Figures 3(b) and 3(c)). CCK-8 assay showed that knockdown of FGFR1 significantly inhibited cell proliferation in OC cells (Figure 3(d)). The effect of FGFR1 on cell apoptosis was also investigated by flow cytometric analysis. The

FIGURE 4: Silencing of FGFR1 suppresses ovarian cancer migration *in vitro* and tumor growth *in vivo*. (a) Representative migration images of FGFR1-silenced and control cells. Original magnification: 200x. Quantification of cells on the lower surface of the membrane was performed. Data are the means $\pm$ SD. (b) Representative wound healing images of FGFR1-silenced and control cells at 0 and 24 h, respectively. The black line outlined the cell boundary. Quantification of wound healing rates was analyzed. Data are the means $\pm$ SD. (c) Mice in the sh-FGFR1 group showed relatively larger tumors compared with those in the control group. * $p < 0.05$; ** $p < 0.01$.

silencing of FGFR1 increased the apoptosis rate of OC cells (Figure 3(f)). Consistent with this, caspase-3/7 activity in OC cells was significantly increased by silencing of FGFR1 (Figure 3(e)). The transwell model and wound healing assays were used to analyze the cell migration of OC cells after knockdown of FGFR1 (Figures 4(a) and 4(b)).

3.6. FGFR1 Suppresses Xenograft Tumor Growth In Vivo. FGFR1 expression was reduced stably using shRNAs. To investigate the effect of FGFR1 *in vivo*, OVCAR8 cells were transplanted into nude mice subcutaneously. The weight and size of tumors formed by sh-FGFR1 cells were significantly decreased in comparison with the tumors formed by the

FIGURE 5: FGFR1 enhances the Hh signaling pathway. (a, b) Kyoto Encyclopedia of Genes and Genome (KEGG) analysis of cDNA microarray showed gene set enrichment after FGFR1 knockdown in OVCAR8 and ES2 cells. (c) The GSEA plot based on the gene expression profiles by comparison of the lower FGFR1 expression group and the higher FGFR1 expression group in the GSE9891 dataset. (d) The Venn diagram of the significantly altered pathways in two OC cells and ovarian tissues. (e) The activity of the Hh signaling pathway was significantly inhibited after knockdown of FGFR1 by a luciferase reporter assay. (f, g) The mRNA expression levels of target genes of the Hh signaling pathway in OC cell lines after knockdown of FGFR1. (h) Schematic summary of the findings presented in this study on the role of FGFR1 in OC. * $p < 0.05$; ** $p < 0.01$.

sh-control group (Figure 4(c)). The results showed that FGFR1 promoted tumor growth in OC.

3.7. FGFR1 Regulates the Hedgehog (Hh) Signaling Pathway. To elucidate the signaling pathways that were significantly altered following the silencing of FGFR1 expression, we performed global gene profiling experiments of the OVCAR8 and ES2 cells after knockdown of FGFR1 using siRNAs. We conducted pathway analysis with the differentially expressed genes in two OC cells. Functional and gene network analysis with differentiated genes revealed significantly altered pathways (Figures 5(a) and 5(b)). Meanwhile, we analyzed a microarray dataset from GSE9891 and divided expression data into two groups named the high expression group ($n = 19$) and low expression group ($n = 20$) according to the expression level of FGFR1. Gene set enrichment analysis (GSEA) using hallmark gene sets was performed and showed striking alterations in several pathways including the Hh signaling pathway (Figure 5(c)). The cross of the significantly altered pathways in two OC cells and ovarian tissues showed that the Hh signaling pathway was significantly altered after FGFR1 knockdown (Figure 5(d)).

To further evaluate whether knockdown of FGFR1 inhibited downstream Hh signaling, the Gli-luciferase reporter was used in luciferase reporter assays. As expected, luciferase reporter assays further confirmed that the activity of the Hh signaling pathway was significantly inhibited after knockdown of FGFR1 (Figure 5(e)). Furthermore, the mRNA expression level of target genes (Gli1 and Gli2) of Hh signaling in FGFR1-reduced OC cells was significantly decreased compared to the control, indicating that FGFR1 silencing inhibited the downstream of the Hh signaling pathway (Figures 5(f) and 5(g)).

4. Discussion

In this study, we observed that FGFR1 was commonly upregulated in both OC cells and tissues compared with normal controls. High FGFR1 predicted poor prognosis in OC and other tumors. In OC cells, FGFR1 expression could be induced by hypoxia via HIF1 α . FGFR1 exhibited oncogenic functions in promoting cell proliferation and cell migration by activating Hh signaling.

FGFR1 was demonstrated to express preferentially in skeletal tissues, and small amounts of FGFR1 mRNA were detected in other tissues such as the heart [2]. In the current study, FGFR1 was highly expressed in OC tissues and other different neoplastic diseases. However, the reason why FGFR1 is upregulated in OC is still unclear. Although DNA copy number amplification partly contributed to the increased expression of FGFR1 in OC, we need more evidence to explain the upregulation of FGFR1. It has been reported that solid tumor frequently encounters hypoxia stress, especially measurable sized solid tumors and the overexpression of HIF1 α has been observed in many tumors [24, 25]. In this study, FGFR1 expression could be induced under hypoxia condition in OC cells, which was consistent with previous study [26]. Our data further demonstrated that HIF1 α was essential for the hypoxia-induced FGFR1

expression by transcriptionally binding to the FGFR1 promoter based on a series of assays.

To evaluate the prognostic value of FGFR1 in OC, we performed Kaplan-Meier survival analysis. High FGFR1 expression was associated with poor prognosis in OC patients. This was consistent with the findings in this study that elevated FGFR1 was an indicator for the poor prognosis in gastric carcinomas.

It was reported that downregulation of FGFR1 decreased cell proliferation by promoting the proportion of cells in G1/G0 phase and decreasing in S and G2/M phases in human laryngocarcinoma cancer and esophageal squamous cell carcinoma [14, 16]. Our data revealed that no significant difference was observed in cell cycle assay. Herein, we explored that FGFR1 promoted cell proliferation, inhibited apoptosis and, promoted cell migration of OC cells. The discrepancy might be due to different mechanisms in specific tumors.

FGFR1 was ever thought to have no effect on ERK1/2 signaling without the intracellular tyrosine kinase domain [7]. However, FGFR1 was identified to enhance ERK1/2 signaling through association of SHP with the receptor's intracellular SH2-binding motif [12]. Our study demonstrated that Hh signaling was activated by FGFR1.

In conclusion, we describe FGFR1 as a crucial factor in the clinical outcome and progression during human OC, indicating it is a novel therapeutic target that can be used for the treatment of OC.

5. Conclusions

Our results demonstrated that FGFR1 was commonly upregulated in OC cells and tissues compared with normal controls. High FGFR1 predicted poor prognosis in OCs. FGFR1 expression could be induced by hypoxia via HIF1 α in OC cells. FGFR1 significantly promoted cell proliferation and migration of OC cells *in vitro* and tumor growth *in vivo*. FGFR1 exhibited oncogenic functions in promoting cell proliferation and cell migration by crosstalk with Hh signaling. Taken together, this study provides valuable insight into FGFR1, which plays an important role in tumor growth and Hh signaling which could serve as potential therapeutic targets for the treatment of OC.

Conflicts of Interest

The authors declare no conflicts.

Authors' Contributions

Haiyan Tai and Zhiyong Wu share co-first authorship.

Acknowledgments

This work was supported by funding from National Key R&D Program of China (2016YFC1303100).

Supplementary Materials

Supplementary Table S1: SiRNAs used in this study. Supplementary Table S2: primers used in this study. Supplementary Table S3: correlations between FGFR1 expression and clinicopathologic features in OC patients. (*Supplementary Materials*)

References

- [1] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2016," *CA: a Cancer Journal for Clinicians*, vol. 66, no. 1, pp. 7–30, 2016.
- [2] B. Trueb, L. Zhuang, S. Taeschler, and M. Wiedemann, "Characterization of FGFR1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues," *Journal of Biological Chemistry*, vol. 278, no. 36, pp. 33857–33865, 2003.
- [3] S.-O. M. Injune Kim, K.-H. Yu, U.-H. Kim, and G. Y. Koh, "A novel fibroblast growth factor receptor-5 preferentially expressed in the pancreas," *Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression*, vol. 1518, no. 1-2, pp. 152–156, 2001.
- [4] J. F. Matthew Sleeman, M. McDonald, S. Yuan et al., "Identification of a new fibroblast growth factor receptor, FGFR5," *Gene*, vol. 271, no. 2, pp. 171–182, 2001.
- [5] B. Trueb, S. C. Neuhaus, S. Baertschi, T. Rieckmann, C. Schild, and S. Taeschler, "Fish possess multiple copies of *fgfr1*, the gene for a novel FGF receptor," *Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression*, vol. 1727, no. 1, pp. 65–74, 2005.
- [6] M. Wiedemann and B. Trueb, "Characterization of a novel protein (FGFR1) from human cartilage related to FGF receptors," *Genomics*, vol. 69, no. 2, pp. 275–279, 2000.
- [7] X. Yang, F. Steinberg, L. Zhuang, R. Bessey, and B. Trueb, "Receptor FGFR1 does not promote cell proliferation but induces cell adhesion," *International Journal of Molecular Medicine*, vol. 38, no. 1, pp. 30–38, 2016.
- [8] L. Zhuang, F. Steinberg, and B. Trueb, "Receptor FGFR1 acts as a tumor suppressor in nude mice when overexpressed in HEK 293 Tet-On cells," *Oncology Letters*, vol. 12, no. 6, pp. 4524–4530, 2016.
- [9] A. Kiba, K. Banno, M. Yanokura et al., "Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment," *The Journal of Obstetrics and Gynaecology Research*, vol. 41, no. 10, pp. 1598–1606, 2015.
- [10] L. Zhuang, A. V. Pandey, P. M. Villiger, and B. Trueb, "Cell-cell fusion induced by the Ig3 domain of receptor FGFR1 in CHO cells," *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, vol. 1853, no. 10, pp. 2273–2285, 2015.
- [11] B. Trueb, R. Amann, and S. D. Gerber, "Role of FGFR1 and other FGF signaling proteins in early kidney development," *Cellular and Molecular Life Sciences*, vol. 70, no. 14, pp. 2505–2518, 2013.
- [12] P. N. Silva, S. M. Altamentova, D. M. Kilkenny, and J. V. Rocheleau, "Fibroblast growth factor receptor like-1 (FGFR1) interacts with SHP-1 phosphatase at insulin secretory granules and induces beta-cell ERK1/2 protein activation," *Journal of Biological Chemistry*, vol. 288, no. 24, pp. 17859–17870, 2013.
- [13] C. L. Barrett, C. DeBoever, K. Jepsen, C. C. Saenz, D. A. Carson, and K. A. Frazer, "Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 112, no. 23, pp. E3050–E3057, 2015.
- [14] J. Zuo, M. Wen, M. Lei, X. Peng, X. Yang, and Z. Liu, "MiR-210 links hypoxia with cell proliferation regulation in human Laryngocarcinoma cancer," *Journal of Cellular Biochemistry*, vol. 116, no. 6, pp. 1039–1049, 2015.
- [15] S. Tsuchiya, "The role of MicroRNA-210 in esophageal squamous cell carcinoma," *Yakugaku Zasshi*, vol. 132, no. 9, pp. 1069–1073, 2012.
- [16] S. Tsuchiya, T. Fujiwara, F. Sato et al., "MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFR1)," *Journal of Biological Chemistry*, vol. 286, no. 1, pp. 420–428, 2011.
- [17] D. Wu and P. Yotnda, "Induction and testing of hypoxia in cell culture," *Journal of Visualized Experiments*, no. 54, 2011.
- [18] E. R. King, C. S. Tung, Y. T. Tsang et al., "The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer," *American Journal of Surgical Pathology*, vol. 35, no. 6, pp. 904–912, 2011.
- [19] S. C. Mok, T. Bonome, V. Vathipadiekal et al., "A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2," *Cancer Cell*, vol. 16, no. 6, pp. 521–532, 2009.
- [20] K. Yoshihara, A. Tajima, D. Komata et al., "Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis," *Cancer Science*, vol. 100, no. 8, pp. 1421–8, 2009.
- [21] R. L. Jensen, "Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target," *Journal of Neuro-Oncology*, vol. 92, no. 3, pp. 317–335, 2009.
- [22] K. Selvendiran, A. Bratasz, M. L. Kuppusamy, M. F. Tazi, B. K. Rivera, and P. Kuppusamy, "Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3," *International Journal of Cancer*, vol. 125, no. 9, pp. 2198–2204, 2009.
- [23] L. H. Higgins, H. G. Withers, A. Garbens et al., "Hypoxia and the metabolic phenotype of prostate cancer cells," *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, vol. 1787, no. 12, pp. 1433–1443, 2009.
- [24] H. Zhong, A. M. De Marzo, E. Laughner et al., "Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases," *Cancer Research*, vol. 59, no. 22, pp. 5830–5835, 1999.
- [25] K. L. Talks, H. Turley, K. C. Gatter et al., "The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages," *The American Journal of Pathology*, vol. 157, no. 2, pp. 411–421, 2000.
- [26] M. Olbryt, A. Habryka, S. Student, M. Jarzab, T. Tyszkiewicz, and K. M. Lisowska, "Global gene expression profiling in three tumor cell lines subjected to experimental cycling and chronic hypoxia," *PLoS One*, vol. 9, no. 8, article e105104, 2014.